Literature DB >> 18295396

Participation of OCT3/4 and beta-catenin during dysgenetic gonadal malignant transformation.

Icela Palma1, Rocio-Yolanda Peña, Alejandra Contreras, Guillermo Ceballos-Reyes, Ninel Coyote, Luis Eraña, Susana Kofman-Alfaro, Gloria Queipo.   

Abstract

Gonadoblastoma (GB) is an in situ tumor consisting of a heterogeneous population of mature and immature germ cells, other cells resembling immature Sertoli/granulosa cells, and Leydig/lutein-like cells, may also be present. GB almost exclusively affects a subset of patients with intersex disorders and in 30% of them overgrowth of the germinal component of the tumor is observed and the lesion is term dysgerminoma/seminoma. Several pathways have been proposed to explain the malignant process, and abnormal OCT3/4 expression is the most robust risk factor for malignant transformation. Some authors have suggested that OCT3/4 and beta-catenin might both be involved in the same oncogenic pathway, as both genes are master regulators of cell differentiation and, overexpression of either gene may result in cancer development. The mechanism by which beta-catenin participates in GB transformation is not completely clear and exploration of the E-cadherin pathway did not conclusively show that this pathway participated in the molecular pathogenesis of GB. Here we analyze seven patients with mixed gonadal dysgenesis and GB, in an effort to elucidate the participation of beta-catenin and E-cadherin, as well as OCT3/4, in the oncogenic pathways involved in the transformation of GB into seminoma/dysgerminoma. We conclude that the proliferation of immature germ cells in GB may be due to an interaction between OCT3/4 and accumulated beta-catenin in the nuclei of the immature germ cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295396     DOI: 10.1016/j.canlet.2008.01.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways.

Authors:  FangJun Yuan; Wenbo Zhou; Can Zou; Zhiyun Zhang; Hongsheng Hu; Zongqing Dai; YouShun Zhang
Journal:  Mol Cell Biochem       Date:  2010-06-15       Impact factor: 3.396

2.  Novel variants of Oct-3/4 gene expressed in mouse somatic cells.

Authors:  Nobuhiko Mizuno; Mitsuko Kosaka
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

3.  Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells.

Authors:  Zhumur Ghosh; Mei Huang; Shijun Hu; Kitchener D Wilson; Devaveena Dey; Joseph C Wu
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

Review 4.  Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging.

Authors:  Nigel G Kooreman; Joseph C Wu
Journal:  J R Soc Interface       Date:  2010-09-29       Impact factor: 4.118

5.  Mono-(2-ethylhexyl) phthalate (MEHP) promotes invasion and migration of human testicular embryonal carcinoma cells.

Authors:  Pei-Li Yao; Yi-Chen Lin; John H Richburg
Journal:  Biol Reprod       Date:  2012-05-31       Impact factor: 4.285

Review 6.  Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery.

Authors:  I Gunaseeli; M X Doss; C Antzelevitch; J Hescheler; A Sachinidis
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

7.  Association of immunohistochemical markers with premalignancy in Gonadal Dysgenesis.

Authors:  Bonnie McCann-Crosby; Sheila Gunn; E O'Brian Smith; Lefkothea Karaviti; M John Hicks
Journal:  Int J Pediatr Endocrinol       Date:  2015-06-15

Review 8.  Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine.

Authors:  Paul S Knoepfler
Journal:  Stem Cells       Date:  2009-05       Impact factor: 6.277

Review 9.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.